Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
RVL Pharmaceuticals plc
Pharmaceutical Preparation ManufacturingUnited States
Last verified 11 months agorvlpharma.com
RVL Pharmaceuticals plc, headquartered in the United States, is a prominent player in the biopharmaceutical industry, specialising in innovative therapies for eye care. Founded in 2018, the company has quickly established itself as a leader in the development of unique ophthalmic products, notably its flagship treatment, Upneeq, which addresses acquired ptosis.
With a focus on enhancing patient outcomes, RVL Pharmaceuticals is dedicated to advancing the field of ophthalmology through cutting-edge research and development. The company has achieved significant milestones, including successful product launches and strategic partnerships that bolster its market position. As RVL continues to expand its operational footprint, it remains committed to delivering high-quality, effective solutions that meet the evolving needs of healthcare professionals and patients alike.
18
DitchCarbon score
-24 vs industry average
RVL Pharmaceuticals plc’s score of 18 is lower than 33% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at RVL Pharmaceuticals plc?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Very Low
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
Industry performance
0.243
02025
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Reported emissions
No reported emissions data is available for RVL Pharmaceuticals plc yet.
RVL Pharmaceuticals plc's reported carbon emissions
RVL Pharmaceuticals plc, headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and climate commitments suggests that RVL Pharmaceuticals may not yet have established a formal framework for addressing its carbon footprint or engaging in sustainability initiatives. As the pharmaceutical industry increasingly prioritises environmental responsibility, it will be essential for RVL Pharmaceuticals to develop and communicate its climate strategy to align with industry standards and stakeholder expectations.
Assessing RVL Pharmaceuticals plc as a supplier or portfolio company?
- See verified emissions data for over 2 million organizations
- View emissions forecasts for RVL Pharmaceuticals plc and the organizations you buy from or invest in
- Get PCAF data quality (DQ) scores, including for private organizations
RVL Pharmaceuticals plc’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for RVL Pharmaceuticals plc yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
See details
Not active
Carbon Disclosure Project
See details
Not active
The Climate Pledge
See details
Not active
UN Global Compact Climate Champions initiative
See details
Not active
RE 100
See details
Not active
Climate Action 100
See details
Not active
Emissions comparison with industry peers
View similar organisationsCompanyCountryIndustryLast updatedScoreDetails
RVL Pharmaceuticals plc11 months ago
18
Need this data for financed emissions?
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more